Print selected from Online session24/07/2003

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | | "Ask CAS" for self-help around the clock |
| NEWS 3 | Feb 24 | PCTGEN now available on STN |
| NEWS 4 | Feb 24 | TEMA now available on STN |
| NEWS 5 | Feb 26 | NTIS now allows simultaneous left and right truncation |
| NEWS 6 | Feb 26 | PCTFULL now contains images |
| NEWS 7 | Mar 04 | SDI PACKAGE for monthly delivery of multifile SDI results |
| NEWS 8 | Mar 24 | PATDPAFULL now available on STN |
| NEWS 9 | Mar 24 | Additional information for trade-named substances without structures available in REGISTRY |
| NEWS 10 | Apr 11 | Display formats in DGENE enhanced |
| NEWS 11 | Apr 14 | MEDLINE Reload |
| NEWS 12 | Apr 17 | Polymer searching in REGISTRY enhanced |
| NEWS 13 | Jun 13 | Indexing from 1947 to 1956 added to records in CA/CAPLUS |
| NEWS 14 | Apr 21 | New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX |
| NEWS 15 | Apr 28 | RDISCLOSURE now available on STN |
| NEWS 16 | May 05 | Pharmacokinetic information and systematic chemical names added to PHAR |
| NEWS 17 | May 15 | MEDLINE file segment of TOXCENTER reloaded |
| NEWS 18 | May 15 | Supporter information for ENCOMPPAT and ENCOMPLIT updated |
| NEWS 19 | May 19 | Simultaneous left and right truncation added to WSCA |
| NEWS 20 | May 19 | RAPRA enhanced with new search field, simultaneous left and right truncation |
| NEWS 21 | Jun 06 | Simultaneous left and right truncation added to CBNB |
| NEWS 22 | Jun 06 | PASCAL enhanced with additional data |
| NEWS 23 | Jun 20 | 2003 edition of the FSTA Thesaurus is now available |
| NEWS 24 | Jun 25 | HSDB has been reloaded |
| NEWS 25 | Jul 16 | Data from 1960-1976 added to RDISCLOSURE |
| NEWS 26 | Jul 21 | Identification of STN records implemented |
| NEWS 27 | Jul 21 | Polymer class term count added to REGISTRY |
| NEWS 28 | Jul 22 | INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available |

| | |
|---|---|
| NEWS EXPRESS | April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

Print selected from Online session24/07/2003

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:48:22 ON 24 JUL 2003

=> file registry

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 13:48:51 ON 24 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUL 2003 HIGHEST RN 553610-78-9
DICTIONARY FILE UPDATES: 23 JUL 2003 HIGHEST RN 553610-78-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 9777920.str

L1 STRUCTURE UPLOADED

=> dl1
DL1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 13:49:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     81 TO ITERATE

100.0% PROCESSED      81 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1081 TO     2159
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 13:49:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1818 TO ITERATE

100.0% PROCESSED    1818 ITERATIONS                               8 ANSWERS
SEARCH TIME: 00.00.01

L3             8 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     148.15     148.36

FILE 'CAPLUS' ENTERED AT 13:49:25 ON 24 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Print selected from Online session24/07/2003



FILE COVERS 1907 - 24 Jul 2003 VOL 139 ISS 4
FILE LAST UPDATED: 23 Jul 2003 (20030723/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 5 L3

=> d abs bib hitstr 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
GI




II




III

AB Title compds. B-NHCONH-L-(M-L1)q (I) [B = (un)substituted pyridyl, quinolinyl, isoquinolinyl; L = 5 or 6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; with proviso that L and L1 contain 0-4 hetero atoms, e.g., N, O and S] and their pharmaceutically acceptable salts were prepd. For example, coupling of aniline II, e.g., prepd. from Et 3-hydroxybenzoate in 4-steps, with bis(trichloromethyl)carbonate followed by 3-tert-butylaniline afforded urea III. In in vitro raf kinase assays, 112-specific examples of compds. I inhibited kinase activity with IC50 values ranging from 10 nM-10 .mu.M. Compds. I are useful for the treatment of cancerous cell growth mediated by raf kinase.
AN 2002:850357 CAPLUS
DN 137:352907
TI Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase for the treatment of tumors and/or cancerous cell growth
IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Robert, Sibley N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.
PA Bayer Corporation, USA

SO U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 758,548.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US 2002165394 | A1 | 20021107 | US 2001-777920 | 20010207 |
| US 2002137774 | A1 | 20020926 | US 2001-907970 | 20010719 |
| WO 2002062763 | A2 | 20020815 | WO 2002-US3361 | 20020207 |
| WO 2002062763 | A3 | 20021010 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | |
|---|---|---|---|
| PRAI | US 1999-115877P | P | 19990113 |
| | US 1999-257266 | B2 | 19990225 |
| | US 1999-425228 | B2 | 19991022 |
| | US 2001-758548 | A2 | 20010112 |
| | US 2001-777920 | A | 20010207 |

OS MARPAT 137:352907
IT **432050-22-1P 432050-23-2P 432050-24-3P**
**432050-27-6P 432050-28-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 432050-22-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 432050-23-2 CAPLUS
CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 432050-24-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 432050-27-6 CAPLUS
CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 432050-28-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AB Title compds. A-D-B (I) [D = NHCONH; A = (un)substituted t-butylpyridyl, etc.; B = (un)substituted bridged cyclic structure, etc.] and analogs were prepd. For instance, 4-tert-butyl-2-aminopyridine was coupled to 4-(4-pyridylmethyl)aniline (CH2Cl2, CDI, 0.degree.) to give N-(4-tert-butylpyridyl)-N'-[4-(4-pyridinylmethyl)phenyl]urea as a white solid. Example compds. had IC50 between 10nM and 10.mu.M for raf kinase. I are useful for the treatment of cancerous cell growth mediated by raf kinase.
AN 2002:832761 CAPLUS
DN 137:337791
TI Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase
IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Sibley, Robert N.; Hatoum-Mokdad, Holia; Monahan, Mary-Katherine; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.
PA Bayer Corporation, USA

SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002085857 | A2 | 20021031 | WO 2002-US12066 | 20020418 |
| WO 2002085857 | A3 | 20030116 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-838285 A 20010420
OS MARPAT 137:337791
IT **432050-22-1P 432050-48-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 432050-22-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 432050-48-1 CAPLUS
CN Urea, N-(2-methoxy-3-quinolinyl)-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
GI



II

AB Title compds., e.g., RNHCONHZOR1 [I; R = C6H4(CMe3)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R1 = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepd. Thus, 4-(H2N)C6H4OC6H4(CONHMe)-4 (prepn. given) was condensed with 3-(Me3C)C6H4NH2 and CO(OCCl3)2 to give title compd. II. Data for biol. activity of title compds. were given.

AN 2002:615574 CAPLUS

DN 137:169425

TI Preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.

PA Bayer Corporation, USA

SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2002062763 | A2 | 20020815 | WO 2002-US3361 | 20020207 |
| | WO 2002062763 | A3 | 20021010 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2002165394 | A1 | 20021107 | US 2001-777920 | 20010207 |
| PRAI | US 2001-777920 | A | 20010207 | | |
| | US 1999-115877P | P | 19990113 | | |
| | US 1999-257266 | B2 | 19990225 | | |
| | US 1999-425228 | B2 | 19991022 | | |
| | US 2001-758548 | A2 | 20010112 | | |

OS MARPAT 137:169425

IT **432050-22-1P 432050-23-2P 432050-24-3P**
**432050-27-6P 432050-28-7P 432050-53-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

RN 432050-22-1 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 432050-23-2 CAPLUS
CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 432050-24-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 432050-27-6 CAPLUS
CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 432050-28-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 432050-53-8 CAPLUS
CN Urea, N-[4-[(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)oxy]phenyl]-N'-(2-methoxy-3-quinolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AB This invention relates to the use of a group of heteroaryl ureas (I; for example, N-(2-methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea) contg. N in treating p38 mediated diseases, and pharmaceutical compns. for use in such therapy. I is A-NHC(O)NH-B or a pharmaceutically acceptable salt thereof, wherein A is a substituted or unsubstituted pyridyl, quinolinyl or isoquinolinyl group, B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 50 C atoms with a cyclic structure bound directly to N, contg. at least 5 cyclic members with 0-4 members of groups consisting of N, O and S. Information about the substituents for A and B are given in the claims. Although the methods of prepn. are not claimed, 37 example prepns. are included as well as examples of prepn. of intermediates. No pharmacol. data is included.
AN 2002:409267 CAPLUS
DN 137:6098
TI Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Sibley, Robert N.; Hatoum-Mokdad, Holia; Monahan, Mary-katherine; Gunn, David E.; Lowinger, Timotthy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.
PA Bayer Corporation, USA
SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U. S. Ser. No. 778,039.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2002065296 | A1 | 20020530 | US 2001-838286 | 20010420 |
| | WO 2002085859 | A1 | 20021031 | WO 2002-US12064 | 20020417 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-115878P P 19990113
US 1999-257265 B1 19990225
US 1999-425229 A2 19991022
US 2001-778039 A2 20010207
US 2001-838286 A 20010420

OS MARPAT 137:6098

IT **432050-22-1P**, N-(2-Methoxy-3-quinolinyl)-N'-[4-(2-(N-Methylcarbamyl)-4-pyridyloxy)phenyl]urea **432050-23-2P**, N-(2-Methoxy-3-quinolyl)-N'-[4-[3-(N-methylcarbamoyl)phenoxy]phenyl]urea **432050-24-3P**, N-(2-Methoxy-3-quinolyl)-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea **432050-27-6P**, N-(2-Methoxy-3-quinolyl)-N'-[4-[3-(N-isopropylcarbamoyl)phenoxy]phenyl]urea **432050-28-7P**, N-(2-Methoxy-3-quinolyl)-N'-[4-[4-methoxy-3-(N-methylcarbamoyl)phenoxy]phenyl]urea **432050-48-1P** **432050-53-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl ureas contg. nitrogen hetero-atoms as p38 kinase inhibitors)

RN 432050-22-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 432050-23-2 CAPLUS
CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 432050-24-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 432050-27-6 CAPLUS
CN Benzamide, 3-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 432050-28-7 CAPLUS
CN Benzamide, 2-methoxy-5-[4-[[[(2-methoxy-3-quinolinyl)amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 432050-48-1 CAPLUS
CN Urea, N-(2-methoxy-3-quinolinyl)-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 432050-53-8 CAPLUS
CN Urea, N-[4-[(2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl)oxy]phenyl]-N'-(2-methoxy-3-quinolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Z = O, S; R1 = alkyl, alkenyl, alkoxy, etc.; R2-R6 = alkyl, alkenyl, alkoxy, etc.; adjacent pair of R2-R6 together with the carbon atoms to which they are attached form (un)substituted carbocyclyl, heterocyclyl; R7 = alkyl, alkenyl, alkoxy, etc.; n = 0-3] and their pharmaceutically acceptable salts which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, were prepd. E.g., treatment of 4-amino-2-methylquinoline with carbonyl diimidazole in CH2Cl2 followed by addn. of 6-amino-2-methylbenzoxazole afforded II which showed pKb > 6.0 against orexin-1 receptor. In particular, compds. I are of potential use in the treatment of obesity including obesity obsd. in Type 2(non-insulin-dependent) diabetes patients and/or sleep disorders.
AN 2000:573791 CAPLUS
DN 133:164009
TI Preparation of phenyl ureas and thioureas as orexin receptor antagonists
IN Coulton, Steven; Johns, Amanda; Porter, Roderick Alan
PA Smithkline Beecham Plc, UK
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2000047577 | A1 | 20000817 | WO 2000-EP1150 | 20000210 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1150977 | A1 | 20011107 | EP 2000-906324 | 20000210 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | JP 2002536445 | T2 | 20021029 | JP 2000-598497 | 20000210 |
| PRAI | GB 1999-3266 | A | 19990212 | | |
| | GB 1999-26430 | A | 19991108 | | |
| | WO 2000-EP1150 | W | 20000210 | | |

OS MARPAT 133:164009
IT **288151-08-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of Ph ureas and thioureas as orexin receptor antagonists)
RN 288151-08-6 CAPLUS
CN Benzoic acid, 5-[[[(8-fluoro-2-methyl-4-quinolinyl)amino]carbonyl]amino]-2-(4-methoxyphenoxy)-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT